Allogene Therapeutics (ALLO) Insider Mayo Buys 144,400 Shares

Stephen Mayo, an insider at Allogene Therapeutics, Inc. (NasdaqGS: ALLO), purchased 144,400 shares of the company on June 18, 2026. This transaction was not planned under a Rule 10b5-1 trading plan. The stock was trading at $2.11 on Wednesday.

Insider Buying and Selling at Allogene Therapeutics, Inc.

On June 18, 2026, several insiders, including Stephen Mayo, made significant purchases of Allogene Therapeutics shares. Mayo acquired 144,400 shares, contributing to a wave of insider buying. Other insiders, such as Joshua Kazam, Elizabeth Barrett, Vicki Sato, and Deborah Messemer, also bought 95,400 shares each. These purchases were made without pre-arranged plans, indicating confidence in the company's future.

Allogene Therapeutics, Inc. Stock Up 24.9%

Shares of Allogene Therapeutics traded near $2.11 on Wednesday. The company has a market capitalization of approximately $724.8 million. It operates in the biotechnology sector, focusing on developing allogeneic T cell therapies for cancer and autoimmune diseases. The stock has a 52-week low of $0.98 and a high of $4.46. Its 50-day moving average is $2.17, while the 200-day moving average is $1.76. The company holds a strong liquidity position with a current ratio of 9.65 and a quick ratio of 9.47, though it is not profitable at present, hence no meaningful P/E ratio.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Allogene Therapeutics. On April 16, 2026, HC Wainwright & Co. maintained a 'buy' rating with a price target of $11.00. Jefferies also maintained a 'buy' rating with a target of $10.00 on April 15, 2026. Meanwhile, Bernstein and Argus Research held 'hold' ratings with a target of $3.85. The consensus among analysts is a 'buy' recommendation with a mean target price of $8.49 from 10 analyst opinions.

About Allogene Therapeutics

Allogene Therapeutics, Inc. is a biotechnology company based in South San Francisco, California. Founded in 2017, it is led by CEO Dr. David D. Chang. The company specializes in developing allogeneic T cell therapies to treat cancer and autoimmune diseases. Allogene's pipeline includes CAR T cell product candidates, such as cema-cel targeting CD19 for large B-cell lymphoma, and ALLO-316 targeting CD70 for renal cell carcinoma.

Bottom Line

Stephen Mayo's recent purchase of 144,400 shares highlights insider confidence in Allogene Therapeutics. The company's focus on innovative cancer therapies and its solid liquidity position make it a subject of interest for investors. Analysts have shown continued support with favorable price targets, reflecting optimism about its future prospects. As always, it's important to remember that insider transactions are just one piece of the investment puzzle.